title: [Survival of patients with diffuse large B-cell lymphoma].
abstract: BACKGROUND
  The overall survival and relapse-free survival have increased with current chemotherapy in patients with non-lymphoma Hodgkin. A useful tool to evaluate projections is the International Prognostic Index. Our aim was to evaluate the relation between the prognosis established with the International Prognostic Index and the survival obtained in two years by patients with diffuse large B-cell lymphoma.
  
  
  METHODS
  An observational, longitudinal, prospective study was carried out. Patients included were those with diagnosis and treated along a year, who, at some point in their evolution, required hospitalization. All the patients received ciclofosfamide, doxorrubicine, vincristine and prednisone; additionally, some of them received rituximab. The follow-up average was 26 months. Survival was estimated with Kaplan-Meier curves.
  
  
  RESULTS
  Forty-nine patients were included and classified according to the International Prognostic Index risk. The survival was 90 % for patients with International Prognostic Index low risk, 66.7 % for the patients with intermediate-low risk, 80 % for patients with intermediate-high risk, and 81 % for patients with high risk. The survival for all risk groups was 77.6 %. When we compared the survival of patients with the expected prognosis through the International Prognostic Index, we obtained p = 0.0000.
  
  
  CONCLUSIONS
  Two years after diagnosis, the survival of patients with diffuse large B-cell lymphoma in the study was better than the prognosis estimated through the International Prognostic Index, and similar to that reported in American studies.
authors.affiliation: Servicio de Medicina Interna, Hospital de Especialidades 25, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León, México. markaxo@hotmail.com.
authors.forename: Arnoldo
authors.initials: A
authors.lastname: Salas-Delgado
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Hernández-Pliego
mesh_terms: D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate
keywords: Diffuse lymphoma large B-cell; International prognostic index